Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine the overall progression-free survival (PFS) in patients
with advanced or metastatic (Stage IIIB - pleural effusion/IV), non-squamous histology NSCLC
treated with metronomic chemotherapy plus Avastin. Also, currently there are no defined
markers that predict for clinical benefit to Avastin. Preliminary studies show that there are
several observations that support the concept of metronomic chemotherapy with or without the
combination of an anti-angiogenic agent. The metronomic chemotherapy with Avastin was shown
to enhance the clinical endpoints of the study (response rate and progressive-free survival).
Proof of metronomic scheduling requires the development of appropriate intermediate surrogate
markers. Several markers will be assessed.